9/23/2020
`
`Medtronic to acquire PercuSurge for $225 million
`
`News | October 19, 2000
`
`Medtronic to acquire PercuSurge for $225 million
`
`In a move that will further enhance its interventional vascular product offerings, Medtronic Inc. (Minneapolis) today announced that it
`will acquire Sunnyvale, CA-based PercuSurge Inc.
`The merger agreement calls for an exchange of stock valued at approximately $225 million. Further financial details were not disclosed.
`
`PercuSurge will join the Medtronic Vascular organization, which is headquartered in Santa Rosa, CA.
`
`"We are excited to be joined by this innovative company, whose embolic protection device is the 'best in class' solution for reducing
`clinical complications associated with embolic debris released during interventional procedures," said Andy Rasdal, president of
`Medtronic Vascular.
`
`"We believe that our technology and excellent clinical results, combined with Medtronic AVE's worldwide operational and field
`infrastructure will result in an extremely rapid adoption of our technology to treat the nearly 200,000 diseased saphenous vein bypass
`grafts that could be treated each year," said Peter Rule, president, CEO and chairman of PercuSurge.
`
`The PercuSurge GuardWire Plus Temporary Occlusion and Aspiration system is designed to allow cardiologists and other interventional
`specialists to capture embolic debris that might otherwise block downstream vessels and branches during interventional procedures and
`damage the heart. It consists of a balloon-tipped guidewire, which is inflated briefly to occlude blood flow and capture any material
`dislodged from the wall of the vessel during placement of a stent upstream. Captured material is then withdrawn by using the
`PercuSurge Export aspiration catheter before the balloon of the GuardWire Plus is deflated and blood flow restored.
`
`The device has been used in over 5,000 procedures since its release in Europe during 1999 and was the first distal protection product to
`be commercialized there. The product's first targeted indication is for the treatment of degenerated saphenous vein grafts that show
`signs of disease following heart bypass surgery.
`
`The GuardWire Plus is an investigational device in the United States, and clinical trials are already underway.
`
`Edited by Ursula Jones
`Managing Editor, Medical Design Online
`
`Like what you are reading?
`Sign up for our free newsletter
`
`Email
`
`I agree to the Terms and Privacy Statement
`
`SIGN ME UP
`
`https://www.meddeviceonline.com/doc/medtronic-to-acquire-percusurge-for-225-milli-0001
`
`1/1
`
`
`Page 1
`
`Teleflex Ex. 2203
`Medtronic v. Teleflex
`
`